[1. Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol 2006; 8: 27-37.10.1215/S1522851705000323]Search in Google Scholar
[2. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 2011; 105: 1414-8.10.1038/bjc.2011.357]Search in Google Scholar
[3. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H. Pathology with clinical correlations of primary central nervous system non-Hodgkin’s lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 1994; 74: 1383-97.10.1002/1097-0142(19940815)74:4<1383::AID-CNCR2820740432>3.0.CO;2-1]Search in Google Scholar
[4. Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med 1993; 119: 1093-104.10.7326/0003-4819-119-11-199312010-00007]Search in Google Scholar
[5. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg 1988; 68: 835-53.10.3171/jns.1988.68.6.0835]Search in Google Scholar
[6. Kachanov DY, Dobrenkov KV, Shamanskaya TV, Abdullaev RT, Savkova RF, et al. Solid tumors in young children in Moscow Region of Russian Federation. Radiol Oncol 2008; 42: 39-44.10.2478/v10019-007-0037-2]Search in Google Scholar
[7. Schabet M. Epidemiology of primary CNS lymphoma. J Neurooncol 1999; 43: 199-201.10.1023/A:1006290032052]Search in Google Scholar
[8. Bhagavathi S, Wilson JD. Primary central nervous system lymphoma. Arch Pathol Lab Med 2008; 132: 1830-44.10.5858/132.11.1830]Search in Google Scholar
[9. Herrlinger U, Schabet M, Clemens M, Kortmann RD, Petersen D, Will BE, et al. Clinical presentation and therapeutic outcome in 26 patients with primary CNS lymphoma. Acta Neurol Scand 1998; 97: 257-64.10.1111/j.1600-0404.1998.tb00647.x]Search in Google Scholar
[10. Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg 2000; 92: 261-6.10.3171/jns.2000.92.2.0261]Search in Google Scholar
[11. Linnert M, Iversen HK, Gehl J. Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy. Radiol Oncol 2012; 46: 271-8.10.2478/v10019-012-0042-y]Search in Google Scholar
[12. Tezcan Y, Koc M. 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors. Radiol Oncol 2011; 45: 213-9.10.2478/v10019-011-0019-2]Search in Google Scholar
[13. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859-63.10.1200/JCO.1998.16.3.859]Search in Google Scholar
[14. Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiation therapy: preliminary results. Neurology 1996; 46: 1757-9.10.1212/WNL.46.6.1757]Search in Google Scholar
[15. Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH, et al. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 1998; 4: 110-24.]Search in Google Scholar
[16. Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt-Wolf I, Helmstaedter C, et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 2001; 71: 118-22.10.1136/jnnp.71.1.118]Search in Google Scholar
[17. Blay JY. Primary cerebral non-Hodgkin lymphoma in non-immunocompromised subjects. Bull Cancer 1997; 84: 976-80.]Search in Google Scholar
[18. Pech IV, Peterson K, Cairncross JG. Chemotherapy for brain tumors. Oncology (Williston Park) 1998; 12: 537-53.]Search in Google Scholar
[19. Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol 2000; 11: 927-37.10.1023/A:1008376412784]Search in Google Scholar
[20. Stanic K, Kovac V. Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana. Radiol Oncol 2010; 44: 213-9.10.2478/v10019-010-0038-4]Search in Google Scholar
[21. Horvat M, Jezersek Novakovic B. Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma. Radiol Oncol 2010; 44: 232-8.10.2478/v10019-010-0044-6]Search in Google Scholar
[22. Gregoric B, Zadnik V, Jezersek Novakovic B. The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. Radiol Oncol 2012; 46: 153-9.10.2478/v10019-012-0002-6]Search in Google Scholar
[23. O’Neill BP, O’Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin’s lymphoma: survival advantages with combined initial therapy. Int J Radiat Oncol Biol Phys 1995; 33: 663-73.10.1016/0360-3016(95)00207-F]Search in Google Scholar
[24. Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol 1996; 14: 556-64.10.1200/JCO.1996.14.2.5568636771]Search in Google Scholar
[25. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivnik A, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002; 58: 1513-20.10.1212/WNL.58.10.151312034789]Search in Google Scholar
[26. Shibamoto Y, Ogino H, Suzuki G, Takemoto M, Araki N, Isobe K, et al. Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985-2004. Neuro Oncol 2008; 10: 560-8.10.1215/15228517-2008-028266622918559969]Search in Google Scholar
[27. Joerger M, Huitema AD, Krähenbühl S, Schellens JH, Cerny T, Reni M, et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102: 673-7.10.1038/sj.bjc.6605559283757420125159]Search in Google Scholar
[28. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz MJ, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23: 5034-43.10.1200/JCO.2005.13.52415955902]Search in Google Scholar
[29. Uhm JE, Kim KH, Yi SY, Chang MH, Park KW, Kong DS, et al. A retrospective study to compare two methotrexate-based ragimens for primary central nervous system lymphoma. Leuk Lymphoma 2009; 50: 1110-8.10.1080/1042819090296477619557631]Search in Google Scholar
[30. Lim T, Kim SJ, Kim K, Lee Ji, Lim do H, Lee DJ, et al. Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. Ann Hematol 2011; 90: 1391-8.10.1007/s00277-011-1225-0321036321479535]Search in Google Scholar
[31. Herrlinger U, Schabet M, Bitzer M, Petersen D, Krauseneck P. Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol 1999; 43: 219-26.10.1023/A:1006298201101]Search in Google Scholar
[32. Shibamoto Y, Sasai K, Oya N, Hiraoka M. Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma: a phase II study. J Neurooncol 1999; 42: 161-7.10.1023/A:1006106530795]Search in Google Scholar
[33. Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: Long-term outcome. J Neurosurg 1994; 81: 188-95.10.3171/jns.1994.81.2.01888027800]Search in Google Scholar
[34. O′Brien PC, Roos, DE, Liew KH, Trotter GE, Barton MB, Walker QJ, et al. Preliminary results of combined chemotherapy and radiotherapy for non-AIDS primary central nervous system lymphoma. Trans-Tasman Radiation Oncology Group. Med J Aust 1996; 165: 424-7.]Search in Google Scholar
[35. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009; 374: 1512-20.10.1016/S0140-6736(09)61416-1]Search in Google Scholar
[36. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, et al. Non-Hodgkin’s lymphoma of the brain: can high-dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992; 23: 9-17.10.1016/0360-3016(92)90538-S]Search in Google Scholar
[37. Laack NN, Ballman KV, Brown PB, O’Neill BP; North Central Cancer Treatment Group. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51. Int J Radiat Oncol Biol Phys 2006; 65: 1429-39.10.1016/j.ijrobp.2006.03.061]Search in Google Scholar
[38. Laperriere NJ, Cerezo L, Milosevic MF, Wong CS, Patterson B, Panzarella T. Primary lymphoma of brain: results of management of a modern cohort with radiation therapy. Radiother Oncol 1997; 43: 247-52.10.1016/S0167-8140(97)00074-1]Search in Google Scholar
[39. Brada M, Hjiyiannakis D, Hines F, Traish D, Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys 1998; 40: 1157-62.10.1016/S0360-3016(98)00002-9]Search in Google Scholar
[40. O’Brien P, Roos D, Pratt G, Liew K, Barton M, Poulsen M, et al. Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. J Clin Oncol 2000; 18: 519-26.10.1200/JCO.2000.18.3.51910653867]Search in Google Scholar
[41. Niemiec M, Głogowski M, Tyc-Szczepaniak D, Wierzchowski M, Kępka L. Characteristics of long-term survivors of brain metastases from lung cancer. Rep Pract Oncol Radiother 2011; 16: 49-53.10.1016/j.rpor.2011.01.002386316524376956]Search in Google Scholar